JBJonathan Willard Bush

Jonathan Willard Bush

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan Willard Bush has a total of 305 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-Cell proteomics discerns patient-specific subpopulations in pediatric B-cell acute lymphoblastic leukemia

    by Farah Jayousi, Felix Kraus, Agustina Conrrero, Jonathan W Bush, Audi Setiadi, Philipp F Lange

    B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, representing ∼30% of pediatric cancers and ∼80-85% of pediatric ALL cases. Despite high remission rates, relapse remains a major challenge, often driven by therapy-resistant subpopulations, which are masked in bulk analysis, thus limiting our understanding of disease progression and optimal therapeutic intervention. Precision oncology enables proteome-level characterization of patient specific cancer samples and their subpopulations, essential for improving prognostic accuracy and individualized therapies. Single-cell proteomics by mass spectrometry (SCP-MS) enables quantification of hundreds to thousands of proteins at single cell level, uncovering cellular programs that may contribute to minimal residual disease (MRD) and relapse. Here, employing single-cell sorting of leukemic cells coupled with high-sensitivity SCP-MS, we profile individual leukemic blasts and normal immature B-cells from pediatric B-ALL bone marrow aspirates alongside age-matched controls. SCP-MS deconvoluted cellular heterogeneity and revealed subpopulations with variable leukemia-marker expression, highlighting its potential for early detection of relapse-prone phenotypes and personalized pediatric therapy.

  • Open Access

    Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcoma

    by Felix K. F. Kommoss, Joyce Yu Han Zhang, Branden J. Lynch, Shary Yuting Chen, Janine Senz, Yana Moscovitz, Lesley A. Hill, Ding Ma, R. Wilder Scott, Jonathan Bush, et al.

    DICER1-related tumor predisposition (DRTP), also known as DICER1 syndrome, encompasses a spectrum of malignancies mainly in children and young adults. Most are sarcomas, exhibiting histological and molecular similarities regardless of their anatomical origins, and only express the RNase IIIb domain-defective DICER1. To uncover their cellular origin and developmental hierarchy, we establish a lineage-traceable genetically engineered mouse model with controlled activation of hemizygous Dicer1 RNase IIIb mutation in Hic1+ mesenchymal stromal cells. This causes renal tumors closely mirroring the developmental continuum of human DRTP sarcoma histologically and molecularly. Spatial single-cell transcriptomic analysis reveals a Hic1+Pdgfra+ Dpt+Pi16+ fibroblastic progenitor population, corresponding to universal fibroblasts subjacent to transitional epithelium of renal collecting ducts, that can undergo rhabdomyoblastic differentiation or become proliferative sarcomatous cells. Investigation of patient samples identifies analogous cell states and developmental trajectories. This study uncovers a fibroblastic origin for DRTP sarcoma and provides a faithful mouse model for future mechanistic and translational investigation.


  • Open Access

    A Real‐World Analysis of Outcomes in CIC‐Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study

    by Talya Wittmann Dayagi, Hagit Peretz Soroka, Alannah Smrke, Rebecca J. Deyell, Xiaolan Feng, Sapna Oberoi, Shantanu Banerji, Jonathan Noujaim, Nicolas Prud'HOmme, Ramy Saleh, et al.

    Introduction: CIC‐rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults. Despite distinct biology, CRS are often treated like Ewing sarcomas with multi‐agent chemotherapy, surgery, and radiotherapy, although the benefits of each remain unclear. We report the impact of treatment on response and survival. Methods: This retrospective multicenter study included patients diagnosed with CRS between 2002 and 2023. Demographic, treatment, and outcome data were collected. Event‐free (EFS) and overall survival (OS) were estimated using Kaplan–Meier analysis; risk factors were assessed via log‐rank tests and Cox regression. Treatment response was assessed using RECIST. Results: Among 27 patients (median age 21.5 years; range 8–83), 14 (52%) had localized and 12 (44%) metastatic disease (1 unknown). In the localized group, 6 (43%) received chemotherapy (Response: 2 complete, CR; 1 partial, PR; 1 mixed, MR; 1 stable, SD; 1 progressive disease, PD); 5 (36%) died—3 (21%) had received chemotherapy. Among metastatic patients, 10 (83%) received chemotherapy (1 CR, 5 PR, 2 MR, 1 PD); 9 died (one without chemotherapy). Local control was achieved in 12/14 (86%) localized and 7/12 (56%) metastatic patients. Only surgical resection was associated with improved OS (HR 0.13; p < 0.01) and EFS (HR 0.26; p < 0.01), particularly with R0 resection (EFS HR 0.23; p = 0.02). At median follow‐up of 18 months, 2‐year EFS was 56% vs. 8% ( p = 0.02) and OS was 67% vs. 23% ( p = 0.02) for localized vs. metastatic disease. Conclusion: Complete resection is critical in CRS. Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology‐driven therapies.


  • Open Access

    Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project

    by Vishal Avinashi, Milli Gupta, Beth A Payne, Haneen Amhaz, Alisha T Temirova, Waqqas Afif, Dhandapani Ashok, Janice Barkey, David Burnett, Jonathan W Bush, et al.

    Background: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus that effects both pediatrics and adult patients in Canada and is increasing in prevalence. No Canadian focused best practice recommendations currently exist to guide clinical practice. Methods: The study used a modified Delphi technique to develop evidence and expert opinion-based recommendations for providing care for patients with EoE. The Delphi process consisted of 3 rounds of quantitative surveys and qualitative consensus meetings. Experts were included in the Delphi if they had experience caring for EoE patients in Canada within one of the following professional groups: allergist, adult gastroenterologists, pathologists, pediatric gastroenterologists, and dieticians. Results: Delphi rounds were completed between May 1, 2024, and June 30, 2024. A total of 31 experts in EoE care from across Canada were recruited to participate in the Delphi consensus process. All participants completed all 3 rounds of Delphi surveys. The final statement includes 38 recommendations for the care of patients with EoE organized into 3 sections: definition, diagnosis, and management. A table of research gaps is provided to stimulate further knowledge development on this topic. Conclusion: This consensus statement includes actionable recommendations to support quality care of patients with EoE at any age across Canada. We encourage EoE centres in Canada to come together in a multidisciplinary form to not only provide clinical care but also do much needed research on Canadian specific topics and gaps in EoE care.


  • Open Access

    Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma

    by Shinya Rai, Gerben Duns, Fabian Frontzek, Jasper C. H. Wong, Yifan Yin, Michael Yu Li, Makoto Kishida, Manabu Fujisawa, Shannon Healy, Elena Viganò, et al.

    Disease-defining signatures in lymphomas, driven by intricate molecular mechanisms, have advanced molecular taxonomies, refined classification, and may guide clinical management; however, the role of these signatures in driving disease hallmarks, including subtype-specific organotropism, remains largely unexplored. Primary mediastinal large B-cell lymphoma (PMBCL) is an exemplary lymphoma characterized by disease manifestations in the thymic niche, unique genetic alterations, and immune escape. Here, we identified interferon regulatory factor 4 (IRF4)–C99R mutations uniquely occurring in PMBCL through mutational meta-analysis of large-scale data sets. By integrating multiomics approaches with genome editing in PMBCL cells, we revealed that IRF4-C99R contributes to a differentiation block phenotype. Specifically, we showed that IRF4-C99R reduces its binding to the interferon-stimulated response element (ISRE) motif within PRDM1, encoding a key transcriptional regulator of B-cell differentiation, resulting in decreased PRDM1 expression. Additionally, IRF4-C99R suppresses Traf2 and Nck-interacting kinase, a key interferon gamma (IFN-γ) pathway regulator, by impairing ISRE motif binding, thereby reducing IFN-γ signaling and increasing thymus and activation-regulated chemokine (TARC) expression, which drives TARC-mediated chemotaxis of T regulatory cells. We also revealed that IRF4-C99R upregulates ephrin type-B receptor 1 (EPHB1) through noncanonical activating protein 1–IRF composite motif binding and showed that overexpression of EPHB1 in an immunocompetent syngeneic lymphoma model influenced organotropism to favor thymic localization, without affecting overall tumor burden. IRF4-C99R mutation–induced phenotypes were validated in primary PMBCL tissues using single-nuclei RNA sequencing, confirming that the molecular mechanisms observed in vitro align with the pathophysiology of PMBCL in patients. Together, these findings demonstrate how a single genetic mutation orchestrates the coordinated regulation of hallmark traits including thymus-specific tropism in PMBCL.


  • Open Access

    Pathology reporting of hepatoblastoma resections: recommendations from the international collaboration on cancer reporting

    by Dolores H López‐Terrada, Fleur Webster, Rita Alaggio, Jonathan W Bush, Soo‐Jin Cho, Ronald R de Krijger, Takeshi Inoue, Allison F O'NEill, Antonio R Perez‐Atayde, Sarangarajan Ranganathan, et al.

    Aims: Hepatoblastoma is the most common primary malignant tumour of the liver diagnosed in children and its incidence is increasing worldwide. Ongoing international clinical trials and scientific collaborative efforts are attempting to standardize the diagnosis, risk stratification and management of young patients diagnosed with this rare cancer, which includes surgical resection of the tumour. Here we report the international consensus‐based dataset for the pathology reporting of hepatoblastoma resection specimens. The dataset was developed under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of international pathology and cancer organizations. Methods and results: According to the ICCR's guidelines for dataset development, an international expert panel including paediatric pathologists and a paediatric oncologist specialized in liver tumours developed a set of core and non‐core data items for hepatoblastoma resection specimens based on critical review and discussion of current evidence available. Members of the panel were specialists working in tertiary paediatric hospitals, central reviewers for international paediatric liver tumours consortia and/or involved in paediatric liver tumour trials expert committees. Commentaries were provided to support each data item, explaining the rationale for selecting them as a ‘core’ or ‘non‐core’ elements, their clinical relevance and highlighting potential areas of lack of evidence, including clinical, macroscopic, microscopic and ancillary testing considerations. The hepatoblastoma dataset was finalized and ratified following international public consultation and is published on the ICCR website for wide implementation. Conclusion: This is the first international dataset developed by an international expert panel for reporting hepatoblastoma resection specimens aimed to promote high‐quality, standardized pathology reporting of these rare paediatric liver tumours. The adoption and implementation of this hepatoblastoma data set, freely available worldwide on the ICCR website ( www.iccr‐cancer.org/data‐sets ), will facilitate accurate reporting and enhance the consistency of data collection, support retrospective and inform prospective research and ultimately help to improve clinical outcomes of children with hepatoblastoma.


  • Open Access

    Spatial and multi-omic profiling reveals genes and pathways associated with cytotoxic lymphocyte infiltration in malignant rhabdoid tumor

    by Marco Marra, Dan Jin, Joshua Dubland, Elizabeth Mullen, James Geller, Jonathan Bush

    Malignant rhabdoid tumors (MRTs) are aggressive pediatric cancers with poor outcomes. MRTs exhibit low tumor mutational burden, yet recent studies reported immune cell infiltration. Here, we used spatial transcriptomics and multi-omic profiling to study immune cell infiltration in MRT samples. We observed a diverse repertoire of candidate tumor antigens (TAs), IRF1 signaling activity and elevated expression of antigen processing and presentation genes, strongly associated with a "hot" tumor immune microenvironment (TIME). Upregulation of factors involved in skeletal muscle development was observed in some MRTs with higher CD8 + T cell infiltration and the ratio of M1/M2 macrophages was positively correlated with cytotoxic lymphocyte infiltration. We identified genes, such as SPP1 , preferentially expressed in tumor-associated macrophages (TAMs) and noted the MITF regulatory network appeared active in the M2-like TAMs.


  • Open Access

    Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe

    by Georgina D Barnabas, Tariq A Bhat, Verena Goebeler, Pascal Leclair, Nadine Azzam, Nicole Melong, Colleen Anderson, Alexis Gom, Seohee An, Enes K Ergin, et al.

    Genomics has transformed the diagnostic landscape of pediatric malignancies by identifying and integrating actionable features that refine diagnosis, classification, and treatment. Yet, translating precision oncology data into effective therapies for hard-to-cure childhood, adolescent, and young adult malignancies remains a significant challenge. We present the case for combining proteomics with patient-derived xenograft models to identify personalized treatment for an adolescent with primary and metastatic spindle epithelial tumor with thymus-like elements (SETTLE). Within two weeks of biopsy, proteomics identified elevated SHMT2 as a target for therapy with the anti-depressant sertraline. Drug response was confirmed within two months using a personalized chicken chorioallantoic membrane model of the patient’s SETTLE tumor. Following failure of cytotoxic chemotherapy and second-line therapy, the patient received sertraline treatment and showed decreased tumor growth rates, albeit with clinically progressive disease. We demonstrate that proteomics and fast-track xenograft models provide supportive pre-clinical data in a clinically meaningful timeframe to impact clinical practice. By this, we show that proteome-guided and functional precision oncology are feasible and valuable complements to the current genome-driven precision oncology practices.


  • Open Access

    Immunohistochemical study of histone protein 3 modification in pediatric osteosarcoma identifies reduced H3K27me3 as a marker of poor treatment response

    by Sebastian Kondratowski, Danielle Cohen, Rebecca J Deyell, Ash Sandhu, Jonathan W Bush

    The most common pediatric primary malignant bone tumor, osteosarcoma, is often described as genetically non-recurrent and heterogeneous. Neoadjuvant chemotherapy is typically followed by resection and assessment of treatment response, which helps inform prognosis. Identifying biomarkers that may impact chemotherapy response and survival could aid in upfront risk stratification and identify patients in highest need of innovative therapies for future clinical trials. Relative to conventional genetics, little is known about osteosarcoma epigenetics. We aimed to characterize the methylation and phosphorylation status in osteosarcoma using histone markers found in primary diagnostic biopsies and their paired metastases. We constructed two tissue microarray sets from 58 primary diagnostic samples and 54 temporally-separated but related metastatic or recurrent samples, with tissue blocks available from 2002–2022. Clinical charts were reviewed for post-therapy necrosis response, presence of metastatic disease or recurrence, and overall survival. We evaluated 6 histone H3 residues using immunohistochemistry, including H3K4me3, H3K9me3, H3K27me2, H3K27me3, H3S10T11phos, and H3S28phos. Tumors were scored with low (<25%) or high (≥25%) nuclear staining of tumor cells. Diagnostic biopsies with low H3K27me3 nuclear staining were associated with poor treatment response (≤90% necrosis) at the time of definitive excision (P<0.05). We observed loss of H3S10T11phos expression in metastatic and recurrent resections specimens compared to the primary tumor (P<0.05). Expression patterns for the remaining histone markers did not show significant associations with disease parameters or survival. Although larger cohort studies are needed, these results support the expanded evaluation of histone markers, particularly H3K27me3 and H3S10T11phos, in osteosarcoma biology and risk stratification.


  • Open Access

    Lack of SMARCB1 expression characterizes a subset of human and murine peripheral T-cell lymphomas

    by Anja Fischer, Thomas K. Albert, Natalia Moreno, Marta Interlandi, Jana Mormann, Selina Glaser, Paurnima Patil, Flavia W. de Faria, Mathis Richter, Archana Verma, et al.

    Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of malignancies with poor outcome. Here, we identify a subgroup, PTCL-NOSSMARCB1-, which is characterized by the lack of the SMARCB1 protein and occurs more frequently in young patients. Human and murine PTCL-NOSSMARCB1- show similar DNA methylation profiles, with hypermethylation of T-cell-related genes and hypomethylation of genes involved in myeloid development. Single-cell analyses of human and murine tumors revealed a rich and complex network of interactions between tumor cells and an immunosuppressive and exhausted tumor microenvironment (TME). In a drug screen, we identified histone deacetylase inhibitors (HDACi) as a class of drugs effective against PTCL-NOSSmarcb1-. In vivo treatment of mouse tumors with SAHA, a pan-HDACi, triggered remodeling of the TME, promoting replenishment of lymphoid compartments and reversal of the exhaustion phenotype. These results provide a rationale for further exploration of HDACi combination therapies targeting PTCL-NOSSMARCB1- within the TME.